Tuesday, December 11, 2012 6:03:19 PM
LONDON | Tue Dec 11, 2012
(Reuters) - Denmark's Novo Nordisk is sizing up a high-price niche market for its drug liraglutide as a weight-loss treatment, with the United States the prime opportunity.
The premium-price approach could turn it into a multibillion-dollar-a-year product, the company believes.
Novo is studying the injected drug - already on the market as a treatment for type-2 diabetes under the brand name Victoza - as a therapy for the seriously obese, with pivotal clinical trial results due in the first half of next year.
While some in the industry are sceptical about using so-called GLP-1 diabetes drugs such as liraglutide to fight obesity, Novo's Chief Science Officer Mads Krogsgaard Thomsen believes the approach can offer cost-effective benefits.
Glucagon-like peptide-1, or GLP-1, drugs work by stimulating insulin release when glucose levels become too high. Their ability to induce weight loss is an added benefit, since type-2 diabetes is linked to obesity.
What is more, the willingness of the U.S. Food and Drug Administration to license new obesity pills from Vivus and Arena Pharmaceuticals last summer shows the door is open to such new medicines, Thomsen said.
"It's positive. More physicians are now knowledgeable that pharmacotherapy can make a difference and the political establishment in the U.S. now knows that behavior change alone is not enough," he said in an interview in London.
More than a third of American adults, or some 100 million people, are obese and the figure is rising fast, posing a growing threat to the nation's health.
Among this population group, liraglutide may help the severely obese, including those with related problems like interrupted breathing during sleep and pre-diabetes, who might otherwise receive stomach surgery.
"We are not going out to treat the 100 million ... We see this as solving a problem in a niche of maybe a few million patients," Thomsen said.
"If you took one million patients and gave them liraglutide at 3.0 milligrams (a day) at the U.S. price that would be a $6 billion market."
When used in diabetes as Victoza, liraglutide is given at daily doses of either 1.2 or 1.8 mg. Novo is betting on a higher dose to produce greater weight-loss in the obese. A key unknown is whether this will produce unacceptable side effects - and Thomsen admits this makes it something of a "joker" in the company's line-up of new products.
The main adverse effect of Victoza is nausea in some patients, although this is not strong enough in itself to account for the weight loss seen with the drug and Thomsen does not see nausea as a hurdle to regulatory approval.
More worrying, would be any evidence that high-dose liraglutide is linked to pancreatitis.
Given the high safety bar required for a new obesity drug, analysts are currently divided as to whether liraglutide will make it for weight loss - especially given past disappointments with diet drugs such as Sanofi's Acomplia.
If all goes according to plan, however, Novo aims to file for approval at the end of next year, implying a potential U.S. launch in late 2014 or early 2015 for a product that would add a new string to the bow of the world's biggest maker of insulin.
billy
Recent NVO News
- Tesla Resolves Autopilot Lawsuit, JPMorgan Unveils Potential CEO Successors, and More • IH Market News • 04/09/2024 10:39:30 AM
- Walgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest News • IH Market News • 03/28/2024 01:48:04 PM
- Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News • IH Market News • 03/26/2024 11:20:49 AM
- Unilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and More • IH Market News • 03/19/2024 11:33:10 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 05:14:09 PM
- Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity • PR Newswire (US) • 03/08/2024 07:57:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 07:53:12 PM
- CNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest News • IH Market News • 03/08/2024 11:19:59 AM
- Tesla Exits Market Top 10, Victoria’s Secret Stock Tumbles 30% on Weak Forecast • IH Market News • 03/07/2024 10:43:17 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 01:29:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 03:50:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 11:38:51 AM
- Cisco Systems Stock Drops 5% Following Restructuring Plan, Berkshire Trims Apple Stake, and Latest News • IH Market News • 02/15/2024 11:34:25 AM
- Cloudflare Skyrockets 26% Pre-Market; Expedia Plunges 14% After CEO Resignation, and More • IH Market News • 02/09/2024 10:51:57 AM
- Arm Achieves Record Revenue, PayPal Shares Plummet by More Than 9%, and Latest Updates • IH Market News • 02/08/2024 11:10:06 AM
- Boeing Faces Strike Threat, Palantir Up 18% After Recording its First Profitable Year, and More • IH Market News • 02/06/2024 11:14:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 12:01:57 PM
- Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). • Edgar (US Regulatory) • 01/31/2024 11:55:28 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/31/2024 11:51:16 AM
- U.S. Futures Waver Ahead of Fed Decision Amid Mixed Corporate Earnings; Oil Prices Slide • IH Market News • 01/31/2024 11:29:30 AM
- Walmart’s Stock Split, Elon Musk’s Billion-Dollar Package Revoked, and More • IH Market News • 01/31/2024 11:28:17 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 11:27:38 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 05:21:11 PM
- Philips Shares Drop 6% as US Sales Halted Following Agreement on Faulty Sleep Apnea Devices, and more Wall Street Highlights • IH Market News • 01/29/2024 11:09:38 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM